Transcatheter Valve Replacement Best for Severe Tricuspid Regurgitation
By Elana Gotkine HealthDay Reporter
MONDAY, Nov. 4, 2024 -- Transcatheter tricuspid-valve replacement is superior to medical therapy alone for patients with severe tricuspid regurgitation, according to a study published online Oct. 30 in the New England Journal of Medicine to coincide with the annual Transcatheter Cardiovascular Therapeutics conference, held from Oct. 27 to 30 in Washington, D.C.
Rebecca T. Hahn, M.D., from the Columbia University Irving Medical Center in New York City, and colleagues randomly assigned 400 patients with severe symptomatic tricuspid regurgitation to undergo transcatheter tricuspid-valve replacement and medical therapy (valve-replacement group) or medical therapy alone (control group; 267 and 133 patients, respectively). All possible patient pairs were compared to calculate the win ratio for the primary outcome.
The researchers found that the win ratio favoring valve replacement was 2.02 at one year. More wins occurred among patients in the valve-replacement group versus the control group with respect to death from any cause (14.8 versus 12.5 percent), postindex tricuspid-valve intervention (3.2 versus 0.6 percent), and improvement in the Kansas City Cardiomyopathy Questionnaire overall summary score (23.1 versus 6.0 percent), New York Heart Association functional class (10.2 versus 0.8 percent), and six-minute walk distance (1.1 versus 0.9 percent). With respect to the annualized rate of hospitalization for heart failure, the valve-replacement group had fewer wins than the control group (9.7 versus 10.0 percent). Severe bleeding occurred in 15.4 and 5.3 percent of the valve-replacement and control groups, respectively.
"In patients with severe tricuspid regurgitation, transcatheter tricuspid-valve replacement plus medical therapy was superior to medical therapy alone," the authors write.
The study was funded by Edwards Lifesciences.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted November 2024
Read this next
More Than One in 10 Surgical Patients Face Food Insecurity
FRIDAY, June 20, 2025 -- Food insecurity is a significant burden among U.S. surgical patients, according to a study published online June 18 in JAMA Surgery. Annabelle...
Survival Up for CABG With Surgical Ablation in Atrial Fibrillation
FRIDAY, June 13, 2025 -- Medicare beneficiaries with preexisting atrial fibrillation undergoing coronary artery bypass grafting (CABG) who undergo concomitant surgical ablation...
ASCO: Durvalumab Plus FLOT Beneficial for Resectable Gastric, GE Junction Cancer
THURSDAY, June 5, 2025 -- For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.